2-amino-5-phosphonovalerate has been researched along with Parkinson Disease in 6 studies
2-Amino-5-phosphonovalerate: The D-enantiomer is a potent and specific antagonist of NMDA glutamate receptors (RECEPTORS, N-METHYL-D-ASPARTATE). The L form is inactive at NMDA receptors but may affect the AP4 (2-amino-4-phosphonobutyrate; APB) excitatory amino acid receptors.
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (50.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hallworth, NE | 1 |
| Bevan, MD | 1 |
| Shen, KZ | 1 |
| Johnson, SW | 1 |
| Carroll, CB | 1 |
| Holloway, V | 1 |
| Brotchie, JM | 1 |
| Mitchell, IJ | 1 |
| Olney, JW | 1 |
| Zorumski, CF | 1 |
| Stewart, GR | 1 |
| Price, MT | 1 |
| Wang, GJ | 1 |
| Labruyere, J | 1 |
| Turski, L | 1 |
| Klockgether, T | 1 |
| Turski, WA | 1 |
| Schwarz, M | 1 |
| Sontag, KH | 1 |
| Steiner, JP | 1 |
| Payne, KB | 1 |
| Main, CD | 1 |
| D'Alfonso, S | 1 |
| Jacobsen, KX | 1 |
| Hicks, TP | 1 |
| Staines, WA | 1 |
| Poulter, MO | 1 |
6 other studies available for 2-amino-5-phosphonovalerate and Parkinson Disease
| Article | Year |
|---|---|
Globus pallidus neurons dynamically regulate the activity pattern of subthalamic nucleus neurons through the frequency-dependent activation of postsynaptic GABAA and GABAB receptors.
Topics: 2-Amino-5-phosphonovalerate; Action Potentials; Animals; Evoked Potentials; Excitatory Amino Acid An | 2005 |
Subthalamic stimulation evokes complex EPSCs in the rat substantia nigra pars reticulata in vitro.
Topics: 2-Amino-5-phosphonovalerate; Action Potentials; Animals; Electric Stimulation; Excitatory Amino Acid | 2006 |
Neurochemical and behavioural investigations of the NMDA receptor-associated glycine site in the rat striatum: functional implications for treatment of parkinsonian symptoms.
Topics: 2-Amino-5-phosphonovalerate; Animals; Behavior, Animal; Binding, Competitive; Corpus Striatum; Dose- | 1995 |
Excitotoxicity of L-dopa and 6-OH-dopa: implications for Parkinson's and Huntington's diseases.
Topics: 2-Amino-5-phosphonovalerate; 6-Cyano-7-nitroquinoxaline-2,3-dione; Animals; Chick Embryo; Dibenzocyc | 1990 |
Blockade of excitatory neurotransmission in the globus pallidus induces rigidity and akinesia in the rat: implications for excitatory neurotransmission in pathogenesis of Parkinson's diseases.
Topics: 2-Amino-5-phosphonovalerate; Amino Acids; Animals; Corpus Striatum; Dose-Response Relationship, Drug | 1990 |
GPI-1046 increases presenilin-1 expression and restores NMDA channel activity.
Topics: Adrenergic Agents; Animals; Corpus Striatum; Disease Models, Animal; Excitatory Amino Acid Antagonis | 2010 |